Evidence map›Paper›PMID 33887983›Full record

SynthesisDiabetes & vascular disease research

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors.

Mei Qiu, Liang-Liang Ding, Miao Zhang, Hai-Rong Zhou

Registry-linked trialOpen access · diamondAbstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Diabetes & vascular disease research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT06072963. Cited by 50 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 4 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06072963 phase2recruiting

Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow: a Feasibility Study

Ran2024Enrolled80Registered outcomes15Posted comparisons0ConditionsAlzheimer Disease, Metabolic Syndrome, Mild Cognitive ImpairmentArmsIntranasal insulin, Intranasal insulin placebo, semaglutide, Semaglutide placebo
PMID 36871874PMID 29687620PMID 30635783PMID 30760178PMID 30868154PMID 30917904PMID 30944040PMID 30984815PMID 31022213PMID 31189511PMID 31924562PMID 32296731other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 4 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Observational
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Mei QiuDepartment of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, China.ORCID 0000-0001-5013-657X
Liang-Liang DingDepartment of Endocrinology, First Affiliated Hospital of Yangtze University, Jingzhou, China.
Miao ZhangDepartment of Nephrology, Shenzhen Hospital of Beijing University of Chinese Medicine, Shenzhen, China.
Hai-Rong ZhouDepartment of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, China.
Longgang Central Hospital · CNBeijing University of Chinese Medicine · CNYangtze University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are no relevant meta-analyses that have assessed the safety of the sodium-glucose transporter 2 (SGLT2) inhibitors in different chronic diseases. We aimed at evaluating the safety of four SGLT2 inhibitors in three chronic diseases by meta-analysis of the large randomized trials of SGLT2 inhibitors. We performed random-effects meta-analysis and carried out subgroup analysis according to type of underlying diseases and type of SGLT2 inhibitors. SGLT2 inhibitors versus placebo significantly reduced the risk of acute kidney injury (RR 0.75, 95% CI 0.66-0.85), and showed the reduced trend in the risk of severe hypoglycemia (RR 0.86, 95% CI 0.71-1.03). SGLT2 inhibitors significantly increased the risks of diabetic ketoacidosis (RR 2.57), genital infection (RR 3.75), and volume depletion (RR 1.14); and showed the increased trends in the risks of fracture (RR 1.07), amputation (RR 1.21), and urinary tract infection (RR 1.07). These effects exhibited by SGLT2 inhibitors were consistent across three chronic diseases (i.e. type 2 diabetes, chronic heart failure, and chronic kidney disease) and four SGLT2 inhibitors (i.e. dapagliflozin, empagliflozin, ertugliflozin, and canagliflozin) (all

Indexed as

Acute Kidney InjuryAmputation, SurgicalDiabetes Mellitus, Type 2Diabetic KetoacidosisFractures, BoneHeart FailureHumansHypoglycemiaPatient SafetyRandomized Controlled Trials as TopicRenal Insufficiency, ChronicReproductive Tract InfectionsRisk AssessmentRisk FactorsSodium-Glucose Transporter 2 InhibitorsTreatment OutcomeSodium-Glucose Transporter 2 Inhibitorsacute kidney injurydiabetic ketoacidosisgenital infectionSGLT2 inhibitorsvolume depletion

Identifiers

PMID33887983
PMCPMC8481734
OpenAlexW3153650031

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.